Sun Pharmaceutical Industries Q2 Results Live: Profit Rises by 27.98% YoY

Sun Pharmaceutical Industries Q2 Results Live : Sun Pharmaceutical Industries declared its Q2 results on October 28, 2024, showcasing a robust financial performance. The company reported a topline growth of 9.01% year-over-year, while profit surged by an impressive 27.98%. This growth indicates a strong recovery and operational efficiency in the current economic climate.

In comparison to the previous quarter, revenue experienced a growth of 5.05%, and profit saw an increase of 7.21%. This sequential growth reflects the company’s ability to maintain momentum in its operations despite market fluctuations.

The Selling, General and Administrative (SG&A) expenses rose slightly by 0.94% quarter-over-quarter and increased by 4.79% year-over-year, indicating a controlled rise in operational costs amidst growing revenue.

Operating income also showed positive trends, with a 6.06% increase quarter-over-quarter and a significant 23.42% increase year-over-year. This suggests that the company is managing its core operations effectively while enhancing profitability.

Earnings per share (EPS) for Q2 stood at ₹12.7, reflecting a notable increase of 28.28% year-over-year, further highlighting the company's strong financial position.

In terms of market performance, Sun Pharmaceutical Industries has delivered a 0.31% return over the past week, a remarkable 25.06% return over the last six months, and an impressive 51.09% year-to-date return, indicating strong investor confidence.

The company currently boasts a market capitalization of ₹456569.5 crore, with a 52-week high of ₹1960.35 and a low of ₹1068.35, showcasing its strong market presence.

As of October 29, 2024, out of 33 analysts covering Sun Pharmaceutical Industries, only 1 analyst has given a 'Sell' rating, while 8 have rated it as 'Hold', 15 as 'Buy', and 9 as 'Strong Buy'. This distribution suggests a strong consensus among analysts for the company’s growth potential.

The consensus recommendation as of October 29, 2024, is to 'Buy', reflecting positive sentiment towards Sun Pharmaceutical Industries in the market.